Ontology highlight
ABSTRACT:
SUBMITTER: Fediuk DJ
PROVIDER: S-EPMC6851892 | biostudies-literature | 2019 Oct
REPOSITORIES: biostudies-literature
Fediuk Daryl J DJ Matschke Kyle K Liang Yali Y Pelletier Kathleen B KB Wei Hua H Shi Haihong H Bass Almasa A Hickman Anne A Terra Steven G SG Zhou Susan S Krishna Rajesh R Sahasrabudhe Vaishali V
Clinical pharmacology in drug development 20190620 7
A fixed-dose combination (FDC) tablet of ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2, and sitagliptin, a dipeptidyl peptidase-4 inhibitor, was developed for the treatment of patients with type 2 diabetes mellitus. Four studies were conducted under fasted conditions to demonstrate bioequivalence of ertugliflozin/sitagliptin FDC tablets and individual components at respective strengths when coadministered in healthy subjects. All studies had open-label, randomized, 2-per ...[more]